11/16
07:42 am
kron
Kronos Bio Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Low
Report
Kronos Bio Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
11/14
04:07 pm
kron
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 [Yahoo! Finance]
Low
Report
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 [Yahoo! Finance]
11/14
04:02 pm
kron
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
Low
Report
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
11/14
08:09 am
kron
Kronos Bio, Inc. (NASDAQ: KRON) was downgraded by analysts at TD Cowen from a "buy" rating to a "hold" rating.
Medium
Report
Kronos Bio, Inc. (NASDAQ: KRON) was downgraded by analysts at TD Cowen from a "buy" rating to a "hold" rating.
11/14
08:09 am
kron
Kronos Bio, Inc. (NASDAQ: KRON) was downgraded by analysts at Piper Sandler from an "overweight" rating to a "neutral" rating. They now have a $1.00 price target on the stock, down previously from $6.00.
Medium
Report
Kronos Bio, Inc. (NASDAQ: KRON) was downgraded by analysts at Piper Sandler from an "overweight" rating to a "neutral" rating. They now have a $1.00 price target on the stock, down previously from $6.00.
11/13
07:22 pm
kron
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Medium
Report
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/13
04:05 pm
kron
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives
Medium
Report
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives
11/5
09:00 am
kron
Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma
Neutral
Report
Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma
10/23
08:58 am
kron
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors [Yahoo! Finance]
Medium
Report
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors [Yahoo! Finance]
10/23
08:55 am
kron
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
Medium
Report
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
10/9
08:55 am
kron
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
Low
Report
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
10/8
11:36 am
kron
Kronos Bio, Inc. (NASDAQ: KRON) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $6.00 price target on the stock.
Medium
Report
Kronos Bio, Inc. (NASDAQ: KRON) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $6.00 price target on the stock.
10/7
09:10 am
kron
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease [Yahoo! Finance]
Low
Report
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease [Yahoo! Finance]
10/7
08:55 am
kron
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease
Low
Report
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease
9/25
09:09 am
kron
Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy [Yahoo! Finance]
Medium
Report
Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy [Yahoo! Finance]
9/25
08:55 am
kron
Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy
Medium
Report
Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy
9/23
08:55 am
kron
Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer
Low
Report
Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer
9/3
08:57 am
kron
Kronos Bio Announces Participation in Medical and Investor Conferences in September [Yahoo! Finance]
Medium
Report
Kronos Bio Announces Participation in Medical and Investor Conferences in September [Yahoo! Finance]
9/3
08:55 am
kron
Kronos Bio Announces Participation in Medical and Investor Conferences in September
Medium
Report
Kronos Bio Announces Participation in Medical and Investor Conferences in September